Brain+ A/S: Brain+ informs of three product releases planned for 2025 and introduces a platform renaming as part of its UK commercialization

Brain+ is fully on-track as communicated to release its CST-Assistant on the UK market as a medical device software by end of September 2024. The CST-Assistant is a proprietary software-based solution for highly scalable offerings of Cognitive Stimulation Therapy (CST), a clinically proven interventional therapy for people with dementia. In parallel with ongoing activities to get ready for UK market entry, Brain+ has developed a product roadmap for 2025 and now introduces three new digital dementia products and services to its pipeline for planned release into the UK in 2025.

As presented below, the next products will broaden Brain+' offerings to people with dementia along the patient pathway, thereby opening access to new customer segments and provide upselling opportunities. More specifically, the objective is to offer patient supporting services, which are accessible from home, offer partial virtual delivery of CST programs for further reach and scalability, and provide services to ease logistics and planning related to CST delivery.  

Devika Wood, Chief Commercial Officer, Brain+ comments:

Our ambition over the next few years is to become a household name for dementia management and treatment. As such, we have embarked on creating a compelling and powerful new brand for Brain+, supporting our launch into the UK market. The rebranding will be shared over the coming weeks, with the introduction of the new name for our product platform - "Ayla".   

The long-term ambition of Brain+ is to build the world's first scalable dementia management platform and become a go-to name for better dementia management. To visually reflect this ambition, the Company has made a rebranding which as a first step aims to attract awareness and support the launch of the CST-Assistant on the UK market. The rebranding includes the introduction of "Ayla" as a memorable and relatable brand name for Brain+' platform of digital dementia offerings. The CST-Assistant, which launches in less than two weeks in the UK, will thus be branded as "Ayla - your CST Assistant".

Simon Nielsen, Chief Strategy & Innovation Officer, Brain+ comments:

We are excited to unveil the next products in our pipeline and the Ayla suite of products to become the world's first scalable, dementia management platform.

Ayla - your CST Home Companion

This product will support people with dementia from home, based on the principles of CST. Initially, the product will be offered to accompany people with dementia, who are enrolled in a CST group program, giving access to supportive material while tracking measures of the users' cognitive wellbeing through the standard 7-weeks of group CST therapy. After the group therapy ends, people with dementia can continue using Ayla - your Home Companion, which will then serve as an ongoing home support tool, while also monitoring the user's wellbeing and feeding this useful information back to healthcare systems.

Later, planned for 2026, a clinically proven home therapy module will be implemented into Ayla - your Home Companion, to offer home-based cognitive therapy with the objective of maintaining the benefits of CST group programs for longer. At this stage,

Ayla - your Home Companion can also be offered earlier in the patient pathway to initiate cognitive therapy earlier than what is the case today. As an example, access to Ayla - your CST Home Companion can be provided as early therapy to a person with cognitive concerns when referred by their doctor to a specialist for further diagnostic tests. Early administration of training is key to obtain better treatment outcomes, and currently patients are facing waiting times of up to half a year between referral and having a specialist consultation.

Ayla - your Virtual CST Assistant

This product will be a virtual adaptation of Ayla - your CST Assistant, which will be made available together with a protocol for how to deliver successful virtual CST to a group of people with dementia. Based on prior successful feasibility studies on delivering virtual CST, Brain+ will partner with Prof. Aimee Spector, the developer of the CST principles, and her team to perform a clinical evaluation of virtual CST group delivery through a randomized controlled trial (RCT). Ayla - your Virtual CST Assistant will extend the capacity of Ayla - your CST Assistant to expand use of the software for virtual delivery. Virtual delivery will significantly expand the reach to patient segments currently not accessible to in-clinic group CST due to medical, geographical or preferential reasons, while lowering the threshold for new sites, and existing sites wishing to scale their CST offering by reducing logistic barriers and footprint in clinics.

Ayla - your CST Planner

The product is a service package for healthcare providers of CST. The intention with this product is to offer an easily accessible software tool to streamline booking, planning and delivery of CST programs; currently a major undertaking in resource-constrained organizations. At first, Ayla - your CST planner will be an easy-to-use web interface for planning and logistics management related to delivering CST, and at a later stage it will be directly connected with the UK Electronic Patient Record (EPR) systems, providing access to Brain+' entire suite of Ayla dementia platform offerings.  Data from the Ayla platform of products will be captured in the Brain+ Data & Analytics backend to provide data feedback loops at multiple stages on the patient pathway, offering patients at home feedback on progress, therapist and specialists information about patient progress, and program managers insights on the performance of their dementia management offerings.  

Contact Information

CEO and Co-founder: Kim Baden-Kristensen, + 45 31 39 33 17 (SMS), kim@brain-plus.com

Brain+ mission: Become the preferred provider of certified health tech solutions for better dementia management, servicing one million people affected by dementia in 2030.